Corvidane is a privately held life sciences company developing patented therapeutic programmes for complex cardiometabolic diseases, including atherosclerosis and MASH. Co-founded by Damion J. Boyer and chemical engineer John M. Burke, the company takes a biology-driven approach aimed at addressing interconnected lipid, inflammatory, and fibrotic disease processes rather than a single target. Its lead programme, CVMB-216, is being advanced through structured preclinical development toward regulated clinical pathways and potential partnerships.
HighTide Therapeutics, IncFounded in 2011 by scientist and entrepreneur Liping Liu, HighTide Therapeutics is a biopharmaceutical company developing multifunctional, multi-targeted therapies for cardiovascular-kidney-metabolic diseases. Its lead candidate, HTD1801, is an oral metabolic modulator built from berberine and ursodeoxycholic acid and is being evaluated in global clinical programs. HighTide also maintains an early-stage research portfolio spanning acute inflammatory disease, weight modulation and neurodegenerative conditions.ROCKVILLE, MD
Kannalife Sciences, IncFounded in 2010 and based at the Pennsylvania Biotechnology Center in Doylestown, Kannalife Sciences develops patented synthetic CBD-inspired therapeutics for neuroinflammation, neuropathic pain and neurodegenerative disease. Its lead investigational molecule, KLS-13019, is being advanced as a potential non-opioid treatment for chemotherapy-induced peripheral neuropathy, with research also examining Parkinson’s disease and other conditions linked to oxidative stress. Kannalife is a wholly owned Neuropathix subsidiary whose scientific team reports more than 75 years of combined pharmaceutical research experience and over 65 jointly held patents.DOYLESTOWN, PA
Neuropathix, IncFounded in 2010 through the creation of Kannalife Sciences, Neuropathix develops synthetic CBD-inspired therapeutics for neuroinflammation, neuropathic pain and neurodegenerative disease. Its lead compound, KLS-13019, is a globally patented non-opioid candidate being advanced from preclinical and IND-enabling research for chemotherapy-induced peripheral neuropathy, with research conducted at the Pennsylvania Biotechnology Center in Doylestown. The company’s scientific team brings more than 75 years of pharmaceutical research experience and holds more than 65 patents jointly.DOYLESTOWN, PA
i-Cordis, LLCFounded by cardiac physicians and scientists, i-Cordis develops immunomodulatory medicines for heart failure with preserved ejection fraction and related cardiovascular diseases. The company is advancing a PEGylated version of pirfenidone, drawing on findings from the Phase II PIROUETTE trial to address the drug’s dosing, tolerability, and pharmacokinetic limitations. Its team combines cardiac immunology with medicinal chemistry and pharmaceutical drug-development experience, and the company has received funding through the NHLBI SBIR Program.